The Women's Health Branding Trap: Why Data Outlasts Authenticity

Authenticity has been a highly requested quality in branding for more than a decade. It has surfaced in nearly every strategy session and has been named a trait a brand should embody. The demand grew out of a shift in how people experience media: after years of curated feeds and the growth of influence into an industry, audiences began to want assurance that the person or brand in front of them matched what it claimed to be. That want turns out to be difficult to satisfy, and the reason is structural.

The authenticity loop

Eugene Healey, in an essay called The Authenticity Delusion, traces the problem to what social media has done to identity. Being constantly perceived turns personal identity into a performance, and each of us becomes a kind of brand, managing how we are seen, so that every action carries the question of how it will land. Authenticity erodes under that self-monitoring because the monitoring itself is a performance. Healey shows that marketing has tried to package the missing quality several times over the past fifteen years. After the financial crisis, brands adopted the "real and relatable" tone of millennial film and television. A purpose-driven register associated with Simon Sinek followed. Most recently, brands have taken on Gen Z's raw and unfiltered aesthetic, and Healey notes the irony that little reads as less authentic than a multinational with billions in market capitalization speaking in the voice of a jaded teenager, a sight now common in comment sections.

Underneath all of these attempts, the same pattern holds steady, where the harder a brand works to demonstrate authenticity, the more that authenticity recedes, because the demonstration becomes the performance the audience has been trained to recognize.

Why this is sharper in women's health

Women's health brands inherit a category built on a promise of straight talk, positioned against a wellness industry that overpromised for years. The audience arrives having been let down before, which makes it unusually alert to sincerity that is performed rather than backed. Language has worn out in the process. "Clinically proven" prompts the question "proven how" more often than it reassures, because too many brands have used clinical-sounding phrasing without clinical-grade evidence to back it up. A brand that leans on tone to signal trustworthiness is competing in the exact register the audience has learned to discount.

The turn toward data and science

A different source of credibility is becoming available, and it comes from substance that the audience can verify. At Women's Health Week, Forbes writer Geri Stengel interviewed Dr. Elina Berglund Scherwitzl, the CEO of Natural Cycles, the first FDA-cleared birth control app, who described how she built a science-first brand. The brand's character rests on regulatory clearance and the evidence behind it, a credibility built on research, validation, and details that the audience can verify. It matches what carries weight in this category, where naming a study size, a mechanism, or a specific endpoint reaches the reader more surely than any adjective, and because evidence is expensive to generate, a competitor cannot reproduce a clearance or a trial with a tone of voice.

Data privacy as part of the substance

Data extends beyond the product to how it is handled, and brands that earn trust treat its protection as part of what they offer. After the Dobbs decision, period and fertility data carry legal exposure that did not exist before, so a brand that has taken specific, verifiable steps, from minimal collection to encryption to deletion options to a refusal to sell, has a substantive position to hold, while a brand that gestures at caring about privacy without those steps is performing again in a place where the audience and regulators can both check the claim.

Why AI raises the stakes

As AI fills marketing channels with fluent, friendly language at near-zero cost, the value of a polished voice falls, because everyone can produce one. What a model cannot manufacture is regulatory clearance, a study, measured data from a wearable, or a privacy architecture. The brands that keep trust as AI spreads will be the ones pointing to something verifiable underneath the words. This is the practical core of the studio's view that strategy matters more, not less, in the age of AI: a sharp strategy decides which substance a brand leads with, and substance is what holds when fluent language becomes free.

The objection: science is slow

The strongest objection to leading with data is that science takes time. A clearance or a trial takes years and significant money to produce; the work does not lend itself to a viral video, and it rarely shows a return within a single funding cycle. A founder under pressure to show traction in twelve months cannot wait for a study to carry the brand.

That objection is correct, and it is why this position remains defensible. The brands that lead on substance absorb a cost most competitors will not, which is why a voice cannot reproduce what they hold. The slowness is part of the moat.

Two things make the position workable. The first is matching the brand to the business it actually is. A company built for clinical outcomes, payor reimbursement, or an employer channel is already operating on a long horizon, and a science-first brand fits that model rather than fighting it, while a company built for fast consumer growth is playing a different game, and asking it to carry clinical seriousness while it chases consumer-speed metrics produces the mismatch that reads as performance. Brand strategy cannot outrun the business model underneath it.

The second is that substance has a near-term form that needs no finished trial. Most early brands do not have a clearance yet, and they do not need one to stop performing. They can name what they measure, describe what their evidence does and does not yet establish, and show the data practices behind the product. Transparency about what is not yet known reads as credibility to an audience that has been promised certainty before. The completed science is the long-term moat, and specificity and transparency are the version available on day one.

It also helps to separate two kinds of data, because they move at different speeds. Collecting measurements from a wearable is fast and cheap, and turning those measurements into validated, regulatory-grade evidence is slow and expensive. A brand can lead with the first kind early, through transparency about what it tracks and how, while it builds toward the second kind that becomes the durable moat.

What this means for a founder

The move is to stop spending effort proving you are authentic and to put that effort into what can be shown. Name the evidence you have and describe what it does and does not establish. Show what you measure and how you handle the data behind it. Let specificity carry the character that a performed voice once carried. The brands that do this will read as trustworthy precisely because they are not asking to be believed on tone.